You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
A non-myeloablative conditioning regimen for hematopoietic stem cell transplantat
SBC: P2D, INC Topic: NHLBIAbstract Hematopoietic stem cell transplantation (HSCT) has become a standard care for the treatment of many hematologic malignancies and non-malignant diseases such as bone marrow failure and immunodeficiency syndromes. Currently, myeloablative or irradiative conditioning regimens are used for enhancing HSC engraftment in transplantation, but they are often associated with significant morbidity a ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Rho GTPase inhibitors for refrigerated platelet storage
SBC: P2D, INC Topic: NHLBIABSTRACT The use of platelet transfusions has increased dramatically since 1980s, but a safe, long-term platelet storage method remains missing. Current practice has platelets stored at 20 to 24 C after preparation, which has a limited lifetime up to 5 days primarily due to concerns about bacterial contamination. Refrigerated storage reduces platelet life-span because it causes glycoprotein-Ib (GP ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Patient Breath Simulator for Capnometer Performance Verification
SBC: WITTING INNOVATION LLC Topic: NHLBIDESCRIPTION (provided by applicant): Capnometers can fail in a number of ways that are not detectable using current static calibration testing procedures. These failures could include leaks in the sample line, a weak sample pump, inadequate dynamic response, flow restriction and flow obstruction. Failure of a capnometer during critical care procedures such as sedation and anesthesia can be life th ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Inter-alpha-inhibitors in Hypoxic-Ischemic Brain Injury
SBC: PROTHERA BIOLOGICS, INC. Topic: NINDSDESCRIPTION (provided by applicant): Neonatal hypoxia-ischemia (HI) remains a major cause of acute perinatal brain injury, leading ultimately to neurologic dysfunction manifesting as cerebral palsy, mental retardation, and epilepsy. Cerebral oxygen deprivation and/or reduced blood flow due to umbilical cord occlusion, prolonged labor, and/or intracranial hemorrhage produce an inflammatory respons ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
99mTc-Tilmanocept for Sentinel Lymph Node Biopsy in Cervical Cancer Surgeries
SBC: Navidea Biopharmaceuticals, Inc. Topic: NCIDESCRIPTION (provided by applicant): Navidea Biopharmaceuticals (Navidea) is seeking SBIR FastTrack grant support to investigate the clinical utility, safety, and efficacy of its new product, 99mTc-tilmanocept, to identify sentinel lymph nodes (SLNs) during surgeries to remove early stage cervical cancers with the intent of improving patient outcomes and reducing post-surgical morbidities in patie ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Liquid Helium Bath Free, Conduction Cooled Nb3Sn Superconducting 7 Tesla Plus Mag
SBC: HYPER TECH RESEARCH INC Topic: NCIDESCRIPTION (provided by applicant): For 7 tesla full body MRI bore magnet systems, NbTi superconductor wire has reached its limit at 4 K. Above 7T if NbTi is used it requires super cooling of helium to 1.8-2.4 K to achieve 7-11T bore MRI and NMR systems.All these 7T full body MRI background magnets sold by Siemens, Philips, and GE have been manufactured by Aligent (formerly known at Varian before ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Single Therapy for Wet AMD and Geographic Atrophy
SBC: Novelmed Therapeutics Inc Topic: NEIDESCRIPTION (provided by applicant): Approximately 85% of the total age-related macular degeneration (AMD) patients have the Dry form. Geographic atrophy (GA) is the advanced form of Dry AMD and is caused by the degeneration of the retinal epithelial cells. While GA is less common than Wet AMD, it is responsible for 10-20% of legal blindness in the US. There is currently no FDA approved treatment ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
HT Label-Free Screening and Kinetic Analysis of Small Molecules and Biologics
SBC: Carterra, Inc. Topic: NIGMSDESCRIPTION (provided by applicant): Real-time label-free technologies such as surface plasmon resonance biosensors provide high-resolution information about the kinetics, affinity, stoichiometry, activity, and specificity, of two (or more) binding partners. While the application f biosensors is well established, current instrumentation has limited sampling throughput. Screens of even a fairly sma ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Preclinical and Clinical Evaluation of Humanized NM9405
SBC: Novelmed Therapeutics Inc Topic: NHLBIABSTRACT NovelMed has developed an anti-properdin antibody (hNM9405) for the treatment of intra and extravascular lysis in paroxysmal nocturnal hemoglobinuria (PNH). The selection of this antibody was based on positive results obtained from in vitro, ex vivo, in vivo, and PK/PD studies in rabbits and primates. These strong positive results have provided a firm foundation for initiation of our Phas ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Combinatorial RXR-based therapeutics for Alzheimer's disease
SBC: REXCEPTOR, INC. Topic: NIADESCRIPTION (provided by applicant): The principle objective of this application is the development of safer and more effective combinatorial therapy for AD. ReXceptor, Inc. is developing new therapeutics for the treatment of AD based on stimulating the physiological clearance mechanisms of soluble forms of A from the brain. Bexarotene is an agonist of the ligand-activated transcription factor, r ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health